Ulcerative Colitis

IWBCA
Feb 19
12 min read

Ulcerative colitis is a chronic inflammatory bowel disease that causes continuous inflammation and ulceration of the inner lining of the colon and rectum, leading to symptoms such as diarrhea, rectal bleeding, abdominal pain, and urgency, with potential long-term complications that can be reduced through early diagnosis, targeted therapy, and regular surveillance.

Overview

What is ulcerative colitis?

Ulcerative colitis (UC) is a chronic inflammatory disease of the large intestine that can quietly reshape a person’s long-term health. It is a leading reason some people begin colorectal cancer screening years earlier and undergo colonoscopy more frequently, because long-standing UC is associated with roughly a two to three times higher risk of colorectal cancer compared with the general population. Over a lifetime, a substantial minority, often estimated at about 15 to 20 percent, ultimately require colectomy because of severe, refractory inflammation, precancerous changes, or emergency complications. UC also increasingly affects younger individuals, and in some pediatric and adolescent groups, more than one-third have inflammation involving the entire colon at the time of diagnosis.

In UC, inflammation is limited to the colon and rectum and typically involves only the innermost mucosal layer of the bowel wall. The disease almost always begins in the rectum and then extends proximally in a continuous pattern without intervening normal segments. This continuous involvement distinguishes UC from Crohn disease, which can affect any part of the gastrointestinal tract and often has skip areas of normal bowel between inflamed segments.

UC is classified as a form of inflammatory bowel disease. It usually begins between ages 15 and 35, although onset can occur in childhood or later adulthood. It is more common in industrialized countries and in urban settings, and its incidence has been rising in many regions worldwide. The clinical course is characterized by flares of active inflammation and periods of remission during which symptoms improve or resolve. With modern therapies, many people achieve prolonged remission and maintain good quality of life, although a subset experiences more aggressive or treatment-resistant disease that requires escalation of therapy, close surveillance, or surgical management.

Symptoms

What are the most common symptoms associated with ulcerative colitis?

UC primarily affects the colon and rectum, so most symptoms relate to changes in bowel habits and rectal bleeding. Systemic symptoms can appear when inflammation is more extensive or severe.

Diarrhea and Stool Frequency: Loose, frequent bowel movements are a hallmark of active UC. People may notice progressively looser stools, sometimes with mucus, and an increased need to pass stool during the day and night.
Rectal Bleeding and Blood in the Stool: Bright red blood on the toilet paper, in the toilet bowl, or mixed with stool is common. Some individuals pass small amounts of blood and mucus even in the absence of formed stool, particularly during flares.
Urgency and Tenesmus: Many people experience an urgent need to defecate with little warning. Tenesmus, the distressing sensation of needing to pass stool even when the rectum is empty, is often reported when inflammation involves the rectum.
Abdominal Pain and Cramping: Crampy abdominal pain, most often in the lower abdomen, can accompany bowel movements or precede them. Pain may improve temporarily after passing stool or gas, then recur as the colon continues to contract.
Change in Bowel Patterns: Some individuals notice alternating loose and more formed stools, a feeling of incomplete evacuation, or a new need to wake at night to use the bathroom. Nighttime bowel movements are particularly suggestive of active inflammatory bowel disease.
Fatigue and Malaise: Chronic inflammation, poor sleep, frequent bathroom trips, and anemia can all contribute to persistent fatigue and a general sense of feeling unwell, even when bowel symptoms are only moderately severe.
Weight Loss and Reduced Appetite: During flares, people may eat less because of pain, nausea, or fear that eating will worsen symptoms. Inflammation itself can also affect appetite and metabolism, occasionally leading to unintentional weight loss.
Fever and Systemic Symptoms in Severe Flares: In more severe disease, low-grade fever, night sweats, and signs of systemic illness may appear. These symptoms can signal a need for prompt medical evaluation to exclude complications such as severe colitis or infection.
Extraintestinal Manifestations: UC can affect organs outside the gut, including joints, skin, eyes, and liver. Some individuals develop painful, swollen joints, red or painful eyes, skin lesions, or liver disease such as primary sclerosing cholangitis. These manifestations can accompany flares or follow a separate course.

Causes

What causes ulcerative colitis?

The exact cause of UC is not fully understood. Current evidence supports a multifactorial model in which genetic susceptibility, immune dysregulation, intestinal barrier abnormalities, and changes in gut microbiota interact with environmental exposures to drive chronic inflammation.

Genetic Susceptibility: Family studies and genome-wide association analyses show that people with UC are more likely to carry specific genetic variants that influence how the immune system responds to microbes and maintains the intestinal barrier. Having a first-degree relative with inflammatory bowel disease increases overall risk, although most affected individuals do not have a strong family history.
Immune System Dysregulation: In UC, the immune system mounts an exaggerated response to antigens in the gut lumen. Instead of maintaining tolerance to commensal bacteria and food proteins, immune cells produce inflammatory mediators that damage the mucosal lining. This process involves both innate and adaptive immunity, including T cells, cytokines, and various signaling pathways.
Intestinal Barrier Dysfunction: The epithelial lining of the colon forms a barrier between the body and the gut contents. In UC, this barrier is often weakened, with increased permeability and impaired mucus production. These defects allow microbial products to penetrate the mucosa and fuel ongoing inflammation.
Altered Gut Microbiota: People with UC often exhibit distinct gut microbiota patterns compared with healthy individuals, including reduced diversity and changes in specific bacterial groups. These alterations may promote inflammation or result from it, and they likely interact with genetic and immune factors to influence disease onset and severity.
Environmental and Lifestyle Factors: Urban living, Western-style diets low in fiber and high in certain fats, prior infections, stress, and some medication exposures appear to modify risk. Smoking has a complex relationship with UC and Crohn disease and is not considered a protective strategy because of broad health harms.
Autoimmune and Autoinflammatory Pathways: UC shares features with other immune-mediated diseases. Some individuals with UC also have extraintestinal autoimmune conditions such as primary sclerosing cholangitis, suggesting overlapping immune pathways. It is likely that multiple immune mechanisms converge to produce the clinical phenotype of UC in genetically susceptible hosts.

Risk Factors

Who is at higher risk of developing ulcerative colitis?

UC can occur in people of any age or background, but certain factors increase the likelihood.

Family History of Inflammatory Bowel Disease: Having a parent, sibling, or child with UC or Crohn's disease increases the likelihood of developing inflammatory bowel disease. This risk reflects shared genetic and possibly environmental influences.
Age and Sex: UC most often begins in late adolescence or early adulthood, with a peak incidence between 15 and 35 years of age. A smaller second peak can occur later in life. Some studies suggest a slight sex difference in certain regions, although patterns vary between populations.
Ethnicity and Geography: UC is more common among people of Northern European ancestry and in high-income countries. However, incidence is rising in many parts of Asia, the Middle East, and Latin America as lifestyles and environments change. Migration from low-incidence to high-incidence regions can increase risk in subsequent generations.
Environmental and Lifestyle Exposures: Urban residence, dietary changes, antibiotic exposure, and early-life environmental factors have been linked to increased risk of inflammatory bowel disease in epidemiologic studies. These factors may shape the gut microbiome and immune development.
Immune-Mediated Comorbidities: People with certain immune-mediated conditions, such as primary sclerosing cholangitis or certain forms of arthritis, have a higher prevalence of UC. In these cases, UC may be identified during evaluation for the associated condition.
Appendectomy and Childhood Infections: The relationship between appendectomy, childhood infections, and UC risk is complex and differs from that in Crohn's disease. Selected studies suggest that appendectomy before UC onset may reduce risk, but this is not a preventive strategy and is not recommended solely for risk modification.

Complications

What complications can ulcerative colitis cause?

Without effective control, UC can lead to complications within the colon and throughout the body. Many risks can be reduced through appropriate medical therapy, surveillance, and timely intervention.

Severe Acute Colitis and Toxic Megacolon: In some individuals, inflammation can rapidly progress, leading to intense pain, frequent bloody stools, systemic illness, and marked elevations in inflammatory markers. Toxic megacolon is a rare but life-threatening complication in which the colon dilates and loses muscular tone, creating a risk of perforation and sepsis that requires urgent hospital care and often surgery.
Colorectal Cancer: Long-standing inflammation in UC increases the risk of colorectal cancer, particularly in people with extensive colitis, disease duration beyond 8 to 10 years, primary sclerosing cholangitis, or a strong family history of colorectal cancer. Historical data suggested very high long-term risks, but more recent studies indicate that, with modern treatment and surveillance, the absolute risk is lower than previously estimated, although it remains higher than in the general population. Estimates suggest that overall colon cancer risk in UC may be roughly 2 to 3 times that of individuals without inflammatory bowel disease. Regular colonoscopic surveillance with targeted biopsies or advanced imaging plays a central role in risk reduction.
Strictures and Colonic Narrowing: Chronic inflammation and healing can lead to scarring and narrowing of the colon. Strictures may cause cramping, bloating, and changes in bowel habits, and they complicate surveillance because cancer can arise within strictured segments.
Perforation and Bleeding: In very active disease, the colon can weaken and perforate, allowing intestinal contents to leak into the abdominal cavity. This is a surgical emergency. Severe bleeding from ulcerated colon segments is less common but can also require urgent intervention.
Extraintestinal Complications: Arthritis, skin diseases such as erythema nodosum and pyoderma gangrenosum, eye inflammation including uveitis and episcleritis, and primary sclerosing cholangitis are among the recognized extraintestinal manifestations. These conditions can cause pain, disability, or progressive organ damage if not recognized and treated.
Nutritional Deficiencies and Low Bone Density: Long-term inflammation, reduced dietary intake, malabsorption, and chronic corticosteroid use can contribute to deficiencies in iron, vitamin B12, folate, vitamin D, and other nutrients. These deficits may lead to anemia, fatigue, and decreased bone mineral density, increasing fracture risk.
Psychological and Social Impact: The unpredictability of flares, the urgency of treatment, and the fear of incontinence can significantly affect work, school, relationships, travel, and social activities. Anxiety, depression, and reduced quality of life are common and deserve proactive attention as part of comprehensive care.

Diagnosis and Tests

How is ulcerative colitis diagnosed?

UC is diagnosed through a combination of clinical assessment, endoscopic evaluation, imaging, and laboratory testing. No single test is definitive on its own, so clinicians look for a consistent pattern across findings.

History and Physical Examination: Diagnosis begins with a detailed history of bowel habits, bleeding, abdominal pain, urgency, nocturnal symptoms, weight changes, extraintestinal complaints, and family history. Physical examination focuses on abdominal tenderness, signs of anemia or malnutrition, perianal findings, and manifestations outside the gut.
Laboratory Tests: Blood tests can reveal anemia, elevated inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate, and abnormalities in electrolytes or liver function. Stool tests help exclude infections, including Clostridioides difficile and other pathogens, which can mimic or exacerbate UC. Fecal calprotectin and lactoferrin levels can serve as noninvasive markers of intestinal inflammation.
Colonoscopy with Biopsy: Colonoscopy is a key diagnostic tool. In UC, endoscopy typically shows continuous inflammation beginning in the rectum and extending proximally, with erythema, friability, loss of vascular markings, erosions, or ulcers. Biopsies from multiple segments are examined under the microscope to confirm chronic inflammatory changes compatible with UC and to exclude alternative diagnoses. Histologic features can also inform assessments of disease activity and cancer risk.
Imaging Studies: Cross-sectional imaging, such as CT or MRI enterography, can help assess disease extent, wall thickness, and complications such as toxic megacolon or perforation, particularly in acute severe colitis. Imaging also helps differentiate UC from Crohn's disease in complex cases.
Differential Diagnosis: Clinicians must distinguish UC from Crohn colitis, infectious colitis, ischemic colitis, and other inflammatory conditions. Patterns of inflammation, histology, small bowel involvement, perianal disease, and response to therapy all contribute to making the correct diagnosis.
Disease Classification and Severity Scoring: UC is often classified by extent as proctitis, left-sided colitis, or extensive or pancolitis. Severity can be graded using clinical and endoscopic indices that consider stool frequency, bleeding, systemic signs, and mucosal appearance. These classifications guide treatment choices and surveillance strategies.

Management and Treatment

How is ulcerative colitis treated and managed over time?

Treatment of UC aims to induce remission during flares, maintain remission to prevent relapse, heal the mucosa, reduce complications, and support quality of life. Therapy is individualized based on disease extent, severity, prior response to medications, comorbidities, and patient preferences.

5-Aminosalicylates (5-ASA) and Topical Therapies: For mild to moderate UC, especially ulcerative proctitis and left-sided disease, oral and rectal 5-ASA agents such as mesalamine are foundational therapies. Rectal suppositories, foams, or enemas can deliver high concentrations of medication directly to the inflamed mucosa, often in combination with oral therapy. These agents are also commonly used for maintenance of remission in mild disease.
Corticosteroids: Oral, rectal, or intravenous corticosteroids are used to induce remission in moderate-to-severe flares or when 5-ASA therapies are insufficient. They are effective for short-term control of inflammation but are not appropriate for long-term maintenance due to significant side effects, including weight gain, osteoporosis, increased infection risk, and metabolic complications.
Immunomodulators: Thiopurines such as azathioprine and 6-mercaptopurine can help maintain remission in some individuals, especially those who are steroid-dependent or have frequent relapses. Their onset of action is slow, and they require careful laboratory monitoring. Methotrexate has a more limited role in UC compared with Crohn's disease.
Biologic Therapies: Biologic agents target specific components of the immune response. Tumor necrosis factor inhibitors, anti-integrin agents, and anti–interleukin-12/23 or anti–interleukin-23 therapies are used for moderate to severe UC, particularly when conventional therapies fail or are not tolerated. These drugs have transformed the management of UC by providing higher rates of mucosal healing and reducing corticosteroid exposure.
Small Molecule Therapies: Oral small molecules, such as Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor modulators, offer additional options for moderate-to-severe UC. They act on intracellular signaling pathways that regulate immune activation and are suitable for induction and maintenance in selected patients.
Surgery: Colectomy with ileal pouch–anal anastomosis or end ileostomy provides a definitive cure for colonic inflammation in UC. Surgery is indicated for medically refractory disease, dysplasia or colorectal cancer, fulminant colitis with complications such as perforation or toxic megacolon, or when quality of life remains poor despite optimized medical therapy. For many, surgery results in substantial symptom relief and reduced cancer risk, although it introduces new anatomic and functional considerations.
Lifestyle, Diet, and Supportive Care: While no single diet cures UC, many people find that certain foods worsen symptoms during flares. Working with clinicians and dietitians to maintain adequate nutrition, avoid trigger foods, and manage lactose or other intolerances is important. Smoking cessation, regular exercise as tolerated, vaccination against preventable infections, and attention to bone health and mental health are integral components of care.
Treat-to-Target and Shared Decision Making: Modern management often follows a treat-to-target approach, aiming for symptom control, normalization of inflammatory markers, and endoscopic healing. Regular review of treatment goals, risks, and benefits through shared decision-making helps align therapy with the individual’s priorities.

Living With Ulcerative Colitis

How can someone live as well as possible with ulcerative colitis day to day?

Living with UC involves medical treatment, self-management skills, and emotional and practical support. Many people, with appropriate therapy, work, study, travel, and participate fully in daily life.

Understanding Personal Disease Patterns: Recognizing early signs of a flare, understanding typical triggers, and knowing when to contact the care team can help prevent prolonged or severe exacerbations. Keeping simple records of symptoms, diet, stressors, and medication adherence can reveal patterns over time.
Medication Adherence and Monitoring: Taking prescribed medications consistently, including maintenance therapies, even when feeling well, is critical. Regular laboratory tests and follow-up visits help monitor for side effects and confirm that inflammation remains controlled.
Nutrition and Hydration: Maintaining adequate calorie, protein, and micronutrient intake supports healing and energy levels. During flares with diarrhea, attention to hydration and electrolyte replacement becomes especially important. Dietitians can assist with individualized plans that respect cultural and personal preferences.
Work, School, and Social Planning: Access to bathrooms, flexible scheduling, and open communication with employers or educators can help manage urgency and fatigue. Some individuals benefit from formal accommodations, particularly during active disease.
Mental Health and Coping: Anxiety and depression are more common in people with chronic inflammatory diseases, including UC. Counseling, peer support groups, and evidence-based strategies for coping with chronic illness can reduce distress and improve functioning. Addressing mental health is as important as treating bowel inflammation.
Long-Term Surveillance and Preventive Care: Adhering to recommended colonoscopy schedules for dysplasia and cancer surveillance, keeping vaccinations up to date, and monitoring bone health and cardiovascular risk are key elements of long-term care. These measures reduce preventable complications and support healthy aging with UC.

Seeking Care

When should someone see a healthcare provider about ulcerative colitis?

Timely evaluation can shorten flares, prevent complications, and support better long-term outcomes.

New or Persistent Bowel Symptoms: Medical evaluation is important if diarrhea, rectal bleeding, abdominal pain, or urgency persists for more than a few weeks, especially if symptoms disrupt sleep or daily activities. Early assessment helps distinguish UC from infections and other causes.
Worsening or Severe Symptoms in Known UC: People with established UC should seek prompt care if they notice a rapid increase in stool frequency, more prominent bleeding, worsening pain, fevers, or an inability to maintain hydration or nutrition. These changes can signal a significant flare or developing complications.
Signs of Severe Colitis or Toxic Megacolon: Severe abdominal pain, marked distension, high fever, very frequent bloody stools, or feeling acutely unwell warrant urgent evaluation, often in an emergency setting. These symptoms may indicate toxic megacolon or impending perforation.
Extraintestinal Symptoms: New eye pain or redness, vision changes, painful, swollen joints, unusual skin lesions, or jaundice require medical attention, as they may represent extraintestinal manifestations or treatment side effects that can be addressed.
Concerns About Medication Side Effects: Symptoms such as severe infection, unexplained bruising or bleeding, shortness of breath, chest pain, severe headache, or mood changes should be discussed promptly with the prescribing clinician, as some therapies carry specific risks that can be mitigated by early intervention.
Routine Follow-Up and Surveillance: Even in remission, regular follow-up with gastroenterology and primary care is essential to review symptoms, adjust therapy as needed, plan colonoscopy surveillance, and address preventive health measures. This ongoing partnership supports stable disease control and timely response to change.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.